Can You Lower Tirzepatide to 5 mg for Maintenance? The 2026 Trial

Reducing tirzepatide after weight loss now has randomized evidence, rather than only anecdotes. In SURMOUNT-MAINTAIN, people who reduced treatment to 5 mg after a long initial treatment period retained more of their original weight reduction than those switched to placebo. Continuing the maximum tolerated dose performed best on average.¹

That makes a lower maintenance dose a legitimate discussion with a prescriber. It does not make 5 mg the right destination for everyone, and it does not validate dividing injections, counting clicks or creating an intermittent schedule.

What SURMOUNT-MAINTAIN tested

The trial used a 60-week initial period on tirzepatide, followed by 52 weeks of randomized maintenance. At randomization, 378 adults continued their maximum tolerated 10 or 15 mg dose, moved to 5 mg, or switched to placebo. At week 112, model-based weight change from the original baseline was −21.9%, −16.6% and −9.9%, respectively. These figures are total change from the original start, not additional weight lost after randomization.¹

The study was funded by Lilly. Its participants had already completed a substantial treatment period; the results cannot be applied automatically to someone who has just started treatment or has not tolerated it.¹

What the result changes

The useful question is no longer simply “continue forever or stop completely?” A person with a reason to reconsider treatment intensity can ask about an approved lower maintenance dose and how their response would be followed. The study supports discussing an alternative; it does not supply your personal dose-reduction instructions.

Do not interpret the average difference as a forecast for one patient. Ask what would count as successful maintenance for you and whether that includes weight stability, appetite, function, glucose control, sleep-apnea outcomes or other clinical goals. A plan based only on the scale can miss the original reason treatment was prescribed.

Why a weekly 5 mg regimen is different from stretching doses

The trial tested specified weekly regimens. It did not establish that injecting every other week produces the same result, or that a fraction of a pen’s contents is equivalent to a manufactured lower-strength dose.¹

The Zepbound label lists 5, 10 and 15 mg as maintenance options for weight reduction, with selection based on response and tolerability. For obstructive sleep apnea, the recommended maintenance doses are 10 or 15 mg. An appropriate weight-maintenance discussion therefore also needs to account for the indication.²

Our dose-selection guide explains the labeled options. For uncertainty about a missed injection, use the separate missed-dose guide rather than treating a missed dose as an intentional maintenance strategy.

What to agree on before making a change

Ask your clinician to document the intended dose, follow-up interval and the changes that would prompt reassessment. Discuss what to do if hunger, weight or a condition being treated worsens. Also ask what happens if insurance or medication access changes, so an administrative interruption does not become an improvised dosing plan.

It is reasonable to discuss side effects, the burden of treatment and complete medication costs. The evidence cannot decide how you value those trade-offs. Our total-cost guide can help distinguish recurring care fees from medication charges before that conversation.

What this study does not answer

It does not prove everyone can maintain their result on 5 mg, establish lifelong outcomes, or show that stopping after a short course is equivalent to ongoing treatment. Read it alongside the withdrawal evidence in our stopping tirzepatide guide. The practical advance is a better-informed choice among supervised options, with a plan to check whether the chosen option works for you.